RNS Number : 9317L
Cambridge Cognition Holdings PLC
10 July 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Results of General Meeting, Total Voting Rights and Director/PDMR Dealing

Cambridge, UK, 10 July 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces that all Resolutions to approve the proposed Placing, Subscription and Open Offer as set out in the Circular published on 24 June 2026, and put to Shareholders at the General Meeting held earlier today, were duly passed.

The proxy voting results of the Resolutions are set out below:

Resolution	FOR		AGAINST	TOTAL		WITHHELD
	No. of votes cast	%	No. of votes cast	%	No. of votes cast	No.
Resolution 1 To grant the directors authority to allot shares pursuant to the Fundraising in the amount set out in the Notice of General Meeting	21,477,868	99.86%	29,988	0.14%	21,507,856	162
Resolution 2 To empower the directors to disapply pre-emption rights on the issue of shares pursuant to the Fundraising in the amount set out in the Notice of General Meeting	21,479,937	99.87%	27,919	0.13%	21,507,856	162

Admission and Settlement

The Company has raised total gross proceeds of approximately £2.6 million in aggregate (before expenses) through the Placing, Subscription and Retail Offer. Application has been made for 7,407,628 New Shares to be admitted to trading on AIM ("**Admission**").

Settlement for and admission of the total of the New Shares is expected to take place, and dealings are expected to commence, at 8:00 a.m. on 13 July 2026.

The New Shares will rank pari passu with the existing Ordinary Shares. Following Admission, the Company will have 54,037,328 Ordinary Shares in issue.

Total Voting Rights

The Company does not currently hold any shares in treasury. Therefore, the above figure of 54,037,328 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Director/PDMR Dealing

Director/PDMR Dealing
Each of the directors has subscribed for shares in the Fundraising. Details of the Ordinary Shares held by each of the Directors, following Admission, are set out in the table below:

Director	Role	New Ordinary Shares being subscribed for	Total Ordinary Shares held on Admission	% of Enlarged Issued Share Capital on Admission
Rob Baker	Chief Executive Officer	11,500	29,852	0.05%
Ronald Openshaw	Chief Financial Officer	114,300	206,044	0.37%
Stuart Gall	Non-Executive Director	28,600	134,050	0.24%
Jon Kempster	Non-Executive Director	28,600	65,300	0.12%
Nick Rodgers	Non-Executive Director	28,600	79,892	0.14%

In addition, to the above, certain senior members of management of the Company have agreed to subscribe for, in aggregate, 55,300 Subscription Shares at the Issue Price.

Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the "Proposed Placing, Subscription and Retail Offer" announcement published by the Company on 24 June 2026.

Rob Baker, CEO, Cambridge Cognition said, "We are grateful for the support of our shareholders as we commence the investment programmes to expand our technology platform to increase shareholder value and bring our technology to the clinicians, patients and consumers who can derive real benefit."

ENQUIRIES

Cambridge Cognition Holdings plc
Rob Baker, Chief Executive Officer
Ronald Openshaw, Chief Financial Officer
Tel: 01223 810700
press@camcog.com

Cavendish Capital Markets Limited (NOMAD and Joint Broker)
Tel: 020 7220 0500
Geoff Nash / Elysia Bough / Joe Smith — Corporate Finance
Harriet Ward — Corporate Broking
Nigel Birks — LS Specialist Sales

Singer Capital Markets Limited (Joint Broker)
Tel: 020 7496 3000
Amber Higgs / James Serjeant / Daniel Ingram

NOTES TO EDITORS

ABOUT CAMBRIDGE COGNITION
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands. These assessments are designed to:

- require minimal specialist administration
- deliver objective results in real time or shortly after completion
- reduce administrator bias
- support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:

- CANTAB One - a brief assessment of overall cognitive function
- CANTAB Insight™ - a three-task battery providing deeper insight across five cognitive sub-domains
- CANTAB Plus - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com

END

ROMURAARNUUBAAR